Abstract：Objective To explore and compare the liver toxicity of antiepileptic drugs Carbamazepine and Oxcarbazepine. Methods The clinical data of 92 epilepsy patients diagnosed and treated in our hospital from January 2016 to January 2017 were retrospectively selected. They were divided into study group (46 cases) and reference group (46 cases) according to different treatment plans. The study group was treated with Oxcarbazepine and the reference group was treated with Carbamazepine. The serum biochemical indicators of alanine aminotransferase (ALT) and the occurrence of clinical symptoms of liver injury were compared between the two groups. Results After treatment, the ALT level in the study group was (29.67±6.54) U/L, which was lower than that in the reference group of (52.08±13.09) U/L, the difference was statistically significant (P＜0.05). The total incidence of clinical liver injury adverse reactions in the study group (2.2%) was lower than that in the reference group (15.2%), the difference was statistically significant (P＜0.05).Conclusion The incidence of liver injury of the new antiepileptic drug Oxcazepine was significantly lower than that of traditional drug Carbamazepine, and the toxicity to liver was lower, worthy of clinical reference and application.
京公网安备 11010502046607号